Export 40 results:
Sort by: Author Title Type [ Year  (Desc)]
Rashad, N., T. Abdelhamid, S. A. Shouman, H. Nassar, M. M. Omran, E. E. D. desouky, and H. Khaled, "Chemo-endocrine therapy as first line treatment for metastatic Hormonal positive metastatic breast cancer: a phase II study.", Clinical Breast Cancer Journal, vol. in press, 2020.
Raghda Y. Abu El-ela, Mostafa M. El-Serafy, M. Yahia, Mervat M. Omran, and S. A. Shouman, "Clinico-pharmacological study of low dose capecitabine and oxaliplatin versus standard XELOX in metastatic colorectal cancer. ", Analysis Medical Science Journal. , vol. 24, issue 105, pp. 3041-3050, 2020.
Marwa Sharaky, M. Kamel, Marwa A. Aziz, M. Omran, Monira M. Rageh, K. A.M.Abouzid, and S. A. Shouman, "Design, synthesis and biological evaluation of a new thieno[2,3-d] pyrimidine-based urea derivative with potential antitumor activity against Tamoxifen sensitive and resistant breast cancer cell lines", Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 35, issue 1, pp. 1641-1656, 2020.
Heba Mansour, M. Omran;, H. Hasan;, and S. E. Kiki, "Modulation of Bleomycin-induced oxidative stress and pulmonary fibrosis by N-acetylcysteine in Rats via AMPK/SIRT1/ NF-KB. ", Clinical and Experimental Pharmacology and Physiology, pp. 1-10, 2020.
Sabri, A., M. Omran, A. S. Azim, R. Abdelfatah, and S. Shouman, "Effect of OCT1 gene polymorphism on response to Imatinib Mesylate in CML patients", Hemasphere, vol. Abstract book, pp. 1919, 2019.
Ibrahim, A. B., H. F.Zaki, W. W. Ibrahim, M. M. Omran, and S. A. Shouman, "Preclinical evaluation of Tamoxifen and Simvastatin as Neo-adjuvant combination therapy for treatment of hormonal dependant breast cancer. ", Toxicology Reports, vol. 6, pp. 1114-1126, 2019.
Ibrahim, A. B., H. F. Zaki, W. W. Ibrahim, M. M. Omran, and S. A. Shouman, "Simvastatin evokes an unpredicted antagonism for tamoxifen in MCF-7 breast cancer cells.", Cancer Management and Research, vol. 11, pp. 10011-10028, 2019.
Omran, M. M., O. Badary, A. Helal, and S. A. Shouman, Pharmacokinetic studies on Docetaxel in Breast Cancer patients , , Germany, Noor Publisher, 2017.
Marzabani, M. A. M., S. A. Shouman, H. A. Moussa, R. A. M. El-Fattah, and M. M. Omran, • Imatinib Pharmacokinetics and its Correlation with Response and Safety in Chronic Myeloid Leukemia Patients, , Giza, Cairo University, 2017.
Omran, M. M., R. M. ABDELFATAH, H. S. Mousa, N. Alieldin, and S. A. Shouman, "Relationship between adherence, drug level and clinical response achieved in patients with chronic myeloid leukemia on imatinib", ESMO2016, Copenhagen- Denmark, 24-26 Oct, 2016.
Omran, M., O. Badary, A. Helal, and S. Shouman, "• A prospective pharmacokinetic study of docetaxel in breast cancer patients in relation to CYP3A4 activity ", Journal of clinical Pharmacology&Biopharmaceutics, vol. 5, issue 2, pp. 1-6, 2016.
Omran, M., O. Badary, A. Helal, H. Hafez, M. Moneer, and S. Shouman, "“A prospective pharmacokinetics study of Docetaxel in breast cancer patients in relation to cytochrome 3A4 activity”", 3rd Congress of the Mediterranean Multidisciplinary Oncology Forum, Athens - Greece, 24-26 Oct, 2013. abstract.docx
Shouman, S. A., O. A. Badary, A. M. Helal, and M. M. Omran, • Pharmacokinetic and Pharmacodynamic studies on Docetaxel in Breast Cancer patients: Role of Cytochrome 3A4 in Relation to Activity, , Cairo, Ain Shams University, 2011.